{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Varrassi G"],"pubmed_abstract":["Palmitoylethanolamide (PEA) has been prescribed in neuropathic pain management for over 20 years. This study aims to summarize what has been published on the topic in the last 15 years and determine the appropriateness of the prescribing. It describes the pharmacological aspect of PEA, especially focusing on its pharmacodynamics and pharmacokinetics. Then, it deeply explores why PEA may be useful in the pharmacological management of both neuropathic and mixed pain. Finally, it examines some innovative patent, which aims to address obstacles encountered with conventional PEA formulations, for its pharmacodynamic characteristics. One of them (Equisetum-PEA) seems promising. It partially ameliorates the bioavailability and the targeted distribution. It seems to introduce novel advancements th"],"journal":["Pain and therapy"],"pagination":["81-101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11751209"],"repository":["biostudies-literature"],"pubmed_title":["A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review."],"pmcid":["PMC11751209"],"pubmed_authors":["Tiso D","Sardo S","Rekatsina M","Cascella M","Finco G","Schweiger V","Fornasari DMM","Paladini A","Varrassi G","Leoni MLG","Corno C"],"additional_accession":[]},"is_claimable":false,"name":"A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review.","description":"Palmitoylethanolamide (PEA) has been prescribed in neuropathic pain management for over 20 years. This study aims to summarize what has been published on the topic in the last 15 years and determine the appropriateness of the prescribing. It describes the pharmacological aspect of PEA, especially focusing on its pharmacodynamics and pharmacokinetics. Then, it deeply explores why PEA may be useful in the pharmacological management of both neuropathic and mixed pain. Finally, it examines some innovative patent, which aims to address obstacles encountered with conventional PEA formulations, for its pharmacodynamic characteristics. One of them (Equisetum-PEA) seems promising. It partially ameliorates the bioavailability and the targeted distribution. It seems to introduce novel advancements th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-25T18:45:06.99Z","creation":"2025-04-06T07:42:57.118Z"},"accession":"S-EPMC11751209","cross_references":{"pubmed":["39630391"],"doi":["10.1007/s40122-024-00685-4"]}}